| Kristen Hubbard, MD | |
|
1598 S County Trl Ste 201, East Greenwich, RI 02818-1762 | |
| (401) 884-0333 | |
| (401) 884-0096 |
| Full Name | Kristen Hubbard |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 12 Years |
| Location | 1598 S County Trl Ste 201, East Greenwich, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033471206 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD14978 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Miriam Hospital | Providence, RI | Hospital |
| Kent County Memorial Hospital | Warwick, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coastal Medical Physicians Inc | 0345658316 | 135 |
News Archive
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.
A team of scientists conducted structural analysis of a newly emerged UK variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They present evidence that suggests that while the new variant has increased infectivity it is not resistant to neutralizing antibodies.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company's proprietary intellectual property for ICT-109 and ICT-37, two of the Company's monoclonal antibody product candidates.
IsoRay, Inc. announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay's final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States.
› Verified 1 days ago
| Entity Name | Coastal Medical Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780273540 PECOS PAC ID: 0345658316 Enrollment ID: O20210427001413 |
News Archive
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.
A team of scientists conducted structural analysis of a newly emerged UK variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They present evidence that suggests that while the new variant has increased infectivity it is not resistant to neutralizing antibodies.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company's proprietary intellectual property for ICT-109 and ICT-37, two of the Company's monoclonal antibody product candidates.
IsoRay, Inc. announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay's final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristen Hubbard, MD 10 Davol Sq, Suite 400, Providence, RI 02903-4754 Ph: (401) 421-4000 | Kristen Hubbard, MD 1598 S County Trl Ste 201, East Greenwich, RI 02818-1762 Ph: (401) 884-0333 |
News Archive
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.
A team of scientists conducted structural analysis of a newly emerged UK variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They present evidence that suggests that while the new variant has increased infectivity it is not resistant to neutralizing antibodies.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company's proprietary intellectual property for ICT-109 and ICT-37, two of the Company's monoclonal antibody product candidates.
IsoRay, Inc. announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay's final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States.
› Verified 1 days ago
Dr. William M Corrao, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1285 S County Trl, East Greenwich, RI 02818 Phone: 401-886-7910 Fax: 401-886-7913 | |
Denise F Glickman, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1672 S County Trl, Suite 303, East Greenwich, RI 02818 Phone: 401-884-0020 Fax: 401-884-0019 | |
Mr. Brian G Abbott, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1377 S County Trl, East Greenwich, RI 02818 Phone: 401-886-7590 Fax: 401-886-7571 | |
Philip M. Trupiano, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1351 S County Trl, Building 2 Suite 220, East Greenwich, RI 02818 Phone: 401-884-4040 Fax: 401-884-4010 | |
Dr. David J Broza, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 3461 S County Trl, East Greenwich, RI 02818 Phone: 401-471-6440 Fax: 401-889-5082 | |
Dr. Shahid A Khan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1351 S County Trl, Suite 215, East Greenwich, RI 02818 Phone: 401-886-9700 Fax: 401-884-4235 |